China Universal Asset Management Company’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $377K | Buy |
42,027
+113
| +0.3% | +$1.01K | 0.04% | 264 |
|
|
2025
Q1 | $314K | Sell |
41,914
-2,006
| -5% | -$15K | 0.03% | 283 |
|
|
2024
Q4 | $330K | Buy |
43,920
+4,129
| +10% | +$31.1K | 0.03% | 289 |
|
|
2024
Q3 | $302K | Buy |
39,791
+15,544
| +64% | +$118K | 0.03% | 269 |
|
|
2024
Q2 | $150K | Sell |
24,247
-15,392
| -39% | -$95.1K | 0.02% | 270 |
|
|
2024
Q1 | $201K | Buy |
39,639
+15,947
| +67% | +$81K | 0.03% | 287 |
|
|
2023
Q4 | $142K | Buy |
23,692
+18,827
| +387% | +$113K | 0.03% | 246 |
|
|
2023
Q3 | $34.4K | Buy |
4,865
+2,388
| +96% | +$16.9K | 0.01% | 254 |
|
|
2023
Q2 | $17.4K | Sell |
2,477
-77
| -3% | -$542 | 0.01% | 281 |
|
|
2023
Q1 | $21.3K | Buy |
2,554
+661
| +35% | +$5.51K | 0.01% | 212 |
|
|
2022
Q4 | $21.7K | Buy |
1,893
+152
| +9% | +$1.75K | 0.01% | 168 |
|
|
2022
Q3 | $22K | Buy |
+1,741
| New | +$22K | 0.01% | 151 |
|